For nearly 50 years, Elsevier�s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2026 edition are many new monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
1. Elsevier’s 2026 Intravenous Medications : A Handbook for Nurses and Health Professionals - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. HOW TO USE - p. iii 6. HOW TO USE THIS BOOK - p. iii 7. Copyright - p. vi 8. Dedication - p. vii 9. PREFACE - p. ix 10. FORMAT AND CONTENT OF INTRAVENOUS MEDICATIONS - p. xiii 11. KEY TO ABBREVIATIONS - p. xvii 12. IMPORTANT IV THERAPY FACTS - p. xix 13. RESOURCES - p. xxi 14. PREPARATION AND ADMINISTRATION OF INJECTABLE DRUGS - p. xxiii 15. IV Drugs - p. xxvi 16. GENERIC DRUGS: A - p. e1 17. A - p. 1 18. ABATACEPT - p. 1 19. ACETAMINOPHEN - p. 4 20. ACETAZOLAMIDE SODIUM - p. 7 21. ACETYLCYSTEINE INJECTION - p. 8 22. ACYCLOVIR - p. 12 23. ADENOSINE - p. 15 24. ADUCANUMAB - p. 19 25. ALBUMIN (HUMAN) - p. 20 26. ALDESLEUKIN - p. 23 27. ALEMTUZUMAB - p. 29 28. ALLOPURINOL SODIUM - p. 37 29. ALPROSTADIL - p. 40 30. ALTEPLASE - p. 42 31. AMIKACIN SULFATE - p. 49 32. AMINOCAPROIC ACID - p. 52 33. AMINOPHYLLINE - p. 54 34. AMIODARONE HYDROCHLORIDE - p. 60 35. AMISULPRIDE - p. 66 36. AMPHOTERICIN B ■ AMPHOTERICIN B LIPID-BASED PRODUCTS - p. 68 37. AMPICILLIN SODIUM AND SULBACTAM SODIUM - p. 73 38. ANGIOTENSIN II INJECTION - p. 76 39. ANIDULAFUNGIN - p. 78 40. ANIFROLUMAB - p. 81 41. ANTIHEMOPHILIC FACTOR (HUMAN ■ RECOMBINANT ■ RECOMBINANT [Fc FUSION PROTEIN] ■ RECOMBINANT [PEGYLATED] ■ RECOMBINANT [PEGYLATED-aucl] ■ RECOMBINANT [SINGLE CHAIN] ■ RECOMBINANT [PORCINE SEQUENCE]) - p. 83 42. ANTIHEMOPHILIC FACTOR ■ VON WILLEBRAND FACTOR COMPLEX (HUMAN) - p. 94 43. ANTITHROMBIN III (HUMAN) - p. 100 44. ANTITHROMBIN RECOMBINANT - p. 103 45. USUAL DOSE (International units [IU]) - p. 103 46. DOSE ADJUSTMENTS - p. 103 47. DILUTION (International units [IU]) - p. 103 48. COMPATIBILITY - p. 104 49. RATE OF ADMINISTRATION (International units [IU]) - p. 104 50. ACTIONS (International units [IU]) - p. 104 51. INDICATIONS AND USES - p. 104 52. CONTRAINDICATIONS - p. 104 53. PRECAUTIONS - p. 104 54. DRUG/LAB INTERACTIONS - p. 105 55. SIDE EFFECTS - p. 105 56. ANTIDOTE - p. 105 57. ANTITHYMOCYTE GLOBULIN (RABBIT) - p. 105 58. ANTIVENIN (LATRODECTUS MACTANS) - p. 108 59. APREPITANT - p. 108.e2 60. ARGATROBAN - p. 110 61. ATEZOLIZUMAB - p. 114 62. ATROPINE SULFATE - p. 121 63. AVELUMAB - p. 123 64. Axatilimab - p. 128 65. AZACITIDINE - p. 130 66. AZITHROMYCIN - p. 134 67. AZTREONAM - p. 137 68. GENERIC DRUGS: B - p. e2 69. B - p. 140 70. GENERIC DRUGS: C - p. e3 71. C - p. 195 72. C1 ESTERASE INHIBITOR (HUMAN OR RECOMBINANT) - p. 195 73. CAFFEINE AND SODIUM BENZOATE - p. 198 74. CAFFEINE CITRATE - p. 198.e2 75. CALASPARGASE PEGOL-mknl - p. 200 76. CALCITRIOL - p. 203 77. CALCIUM CHLORIDE - p. 206 78. CALCIUM GLUCONATE - p. 208 79. CANGRELOR - p. 211 80. CARBOPLATIN - p. 213 81. CARFILZOMIB - p. 216 82. CARMUSTINE (BCNU) - p. 216.e10 83. CASIMERSEN - p. 219 84. CASPOFUNGIN ACETATE - p. 220 85. CEFAZOLIN SODIUM - p. 224 86. CEFEPIME AND ENMETAZOBACTAM - p. 227 87. CEFEPIME HYDROCHLORIDE - p. 229 88. CEFIDEROCOL - p. 233 89. CEFOTAXIME SODIUM - p. 236 90. CEFOTETAN DISODIUM - p. 239 91. CEFOXITIN SODIUM - p. 242 92. CEFTAROLINE FOSAMIL - p. 246 93. CEFTAZIDIME - p. 249 94. CEFTAZIDIME/AVIBACTAM - p. 253 95. CEFTOBIPROLE MEDOCARIL - p. 257 96. CEFTOLOZANE/TAZOBACTAM - p. 260 97. CEFTRIAXONE SODIUM - p. 262 98. CEFUROXIME SODIUM - p. 266 99. CEMIPLIMAB-rwlc - p. 269 100. CENTRUROIDES (SCORPION) IMMUNE F(ab’)2 (EQUINE) INJECTION - p. 273 101. CETIRIZINE HYDROCHLORIDE - p. 273.e2 102. CETUXIMAB - p. 274 103. CHLORAMPHENICOL SODIUM SUCCINATE - p. 279 104. USUAL DOSE - p. 279.e1 105. NEONATAL DOSE - p. 279.e1 106. DOSE ADJUSTMENTS - p. 279.e1 107. DILUTION - p. 279.e1 108. COMPATIBILITY - p. 279.e1 109. RATE OF ADMINISTRATION - p. 279.e1 110. ACTIONS - p. 279.e1 111. INDICATIONS AND USES - p. 279.e2 112. CONTRAINDICATIONS - p. 279.e2 113. PRECAUTIONS - p. 279.e2 114. DRUG/LAB INTERACTIONS - p. 279.e3 115. SIDE EFFECTS - p. 279.e3 116. ANTIDOTE - p. 279.e3 117. CHLOROTHIAZIDE SODIUM - p. 279.e3 118. CHLORPROMAZINE HYDROCHLORIDE - p. 281 119. CIPROFLOXACIN - p. 285 120. CISPLATIN - p. 291 121. CLADRIBINE - p. 294 122. CLEVIDIPINE BUTYRATE - p. 297 123. CLINDAMYCIN PHOSPHATE - p. 299 124. CLOFARABINE - p. 302 125. COAGULATION FACTOR VIIa (RECOMBINANT) RTS - p. 306 126. COAGULATION FACTOR X (HUMAN) - p. 309 127. COAGULATION FACTOR Xa (RECOMBINANT), INACTIVATED-zhzo - p. 312 128. COLISTIMETHATE SODIUM - p. 314 129. CONIVAPTAN HYDROCHLORIDE - p. 317 130. CONJUGATED ESTROGENS - p. 319 131. COPANLISIB - p. 319.e3 132. CORTICORELIN OVINE TRIFLUTATE - p. 319.e7 133. COSYNTROPIN - p. 319.e9 134. CRIZANLIZUMAB-tmca INJECTION - p. 320 135. CROTALIDAE IMMUNE F(ab’)2 (EQUINE) - p. 320.e2 136. CYCLOPHOSPHAMIDE - p. 320.e4 137. CYCLOSPORINE - p. 325 138. CYSTEINE HYDROCHLORIDE - p. 329 139. CYTARABINE - p. 333 140. CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) - p. 336 141. GENERIC DRUGS: D - p. e4 142. D - p. 338 143. DACARBAZINE - p. 338 144. DACTINOMYCIN - p. 339 145. DALBAVANCIN - p. 339.e3 146. DANTROLENE SODIUM - p. 341 147. DAPTOMYCIN - p. 344 148. DARATUMUMAB - p. 349 149. DARBEPOETIN ALFA - p. 349.e6 150. DAUNORUBICIN AND CYTARABINE LIPOSOME FOR INJECTION - p. 355 151. DAUNORUBICIN HYDROCHLORIDE ■ DAUNORUBICIN CITRATE LIPOSOMAL INJECTION - p. 359 152. DECITABINE FOR INJECTION - p. 362 153. DEFEROXAMINE MESYLATE - p. 365 154. DEFIBROTIDE - p. 365.e3 155. DELAFLOXACIN - p. 365.e6 156. DENILEUKIN DIFTITOX - p. 369 157. DESMOPRESSIN ACETATE - p. 369.e3 158. DEXAMETHASONE SODIUM PHOSPHATE - p. 372 159. DEXRAZOXANE - p. 377 160. DEXTRAN 1 - p. 380 161. DEXTRAN HIGH MOLECULAR WEIGHT - p. 380.e1 162. DEXTRAN LOW MOLECULAR WEIGHT - p. 382 163. DEXTROSE - p. 383 164. DIAZEPAM - p. 387 165. DIAZOXIDE - p. 390 166. DIFELIKEFALIN - p. 390.e2 167. DIGOXIN - p. 391 168. DIGOXIN IMMUNE FAB (OVINE) - p. 397 169. DIHYDROERGOTAMINE MESYLATE - p. 399 170. DILTIAZEM HYDROCHLORIDE - p. 401 171. DIMENHYDRINATE - p. 405 172. DINUTUXIMAB - p. 405.e2 173. DIPHENHYDRAMINE HYDROCHLORIDE - p. 410 174. DIPHTHERIA ANTITOXIN - p. 412 175. DIPYRIDAMOLE - p. 412.e2 176. USUAL DOSE - p. 413 177. DILUTION - p. 413 178. COMPATIBILITY - p. 413 179. RATE OF ADMINISTRATION - p. 413 180. ACTIONS - p. 413 181. INDICATIONS AND USES - p. 413 182. CONTRAINDICATIONS - p. 413 183. PRECAUTIONS - p. 413 184. DRUG/LAB INTERACTIONS - p. 414 185. SIDE EFFECTS - p. 414 186. ANTIDOTE - p. 414 187. DOBUTAMINE HYDROCHLORIDE - p. 414 188. DOCETAXEL - p. 417 189. Donanemab - p. 425 190. DOPAMINE HYDROCHLORIDE - p. 429 191. DOXAPRAM HYDROCHLORIDE - p. 433 192. DOXERCALCIFEROL - p. 433.e4 193. DOXORUBICIN HYDROCHLORIDE ■ DOXORUBICIN HYDROCHLORIDE LIPOSOMAL INJECTION - p. 437 194. DOXYCYCLINE HYCLATE - p. 443 195. DROPERIDOL - p. 446 196. DURVALUMAB - p. 446.e3 197. GENERIC DRUGS: E - p. e5 198. E - p. 451 199. GENERIC DRUGS: F - p. e6 200. F - p. 522 201. GENERIC DRUGS: G - p. e7 202. G - p. 595 203. GENERIC DRUGS: H - p. e8 204. H - p. 623 205. GENERIC DRUGS: I - p. e9 206. I - p. 648 207. IBALIZUMAB-uiyk - p. 648 208. IBANDRONATE SODIUM - p. 649 209. IBUPROFEN - p. 652 210. IBUPROFEN LYSINE - p. 656 211. IBUTILIDE FUMARATE - p. 658 212. IDARUBICIN HYDROCHLORIDE - p. 660 213. IDARUCIZUMAB - p. 663 214. IDURSULFASE - p. 665 215. IFOSFAMIDE - p. 665.e3 216. IMETELSTAT - p. 669 217. IMIGLUCERASE ■ VELAGLUCERASE ALFA - p. 671 218. IMIPENEM-CILASTATIN - p. 671.e4 219. IMIPENEM, CILASTATIN, AND RELEBACTAM - p. 675 220. IMMUNE GLOBULIN INTRAVENOUS - p. 679 221. INDOMETHACIN SODIUM - p. 688 222. INFLIXIMAB ■ INFLIXIMAB-dyyb ■ INFLIXIMAB-abda ■ INFLIXIMAB-axxq ■ INFLIXIMAB-qbtx - p. 691 223. INSULIN HUMAN ASPART or LISPRO or GLULISINE - p. 697 224. INOTUZUMAB OZOGAMICIN - p. 701 225. INSULIN HUMAN INJECTION (REGULAR) - p. 701.e5 226. INTERFERON ALFA-2b, RECOMBINANT - p. 705 227. IPILIMUMAB - p. 705.e4 228. IRINOTECAN HYDROCHLORIDE ■ IRINOTECAN LIPOSOME INJECTION - p. 706 229. IRON DEXTRAN INJECTION - p. 715 230. IRON SUCROSE - p. 717 231. ISATUXIMAB - p. 721 232. ISAVUCONAZONIUM SULFATE - p. 722 233. ISOPROTERENOL HYDROCHLORIDE - p. 725 234. USUAL DOSE - p. 726 235. PEDIATRIC DOSE - p. 727 236. DOSE ADJUSTMENTS - p. 727 237. DILUTION - p. 727 238. COMPATIBILITY - p. 727 239. RATE OF ADMINISTRATION - p. 727 240. ACTIONS - p. 727 241. INDICATIONS AND USES - p. 728 242. CONTRAINDICATIONS - p. 728 243. PRECAUTIONS - p. 728 244. DRUG/LAB INTERACTIONS - p. 729 245. SIDE EFFECTS - p. 729 246. ANTIDOTE - p. 729 247. IXABEPILONE - p. 729 248. GENERIC DRUGS: K - p. e10 249. K - p. 734 250. GENERIC DRUGS: L - p. e11 251. L - p. 736 252. GENERIC DRUGS: M - p. e12 253. M - p. 776 254. MAGNESIUM SULFATE - p. 776 255. MANNITOL - p. 779 256. MECHLORETHAMINE HYDROCHLORIDE - p. 783 257. MELOXICAM INJECTION - p. 783.e2 258. MEPERIDINE HYDROCHLORIDE - p. 786 259. MEROPENEM - p. 786.e5 260. MEROPENEM AND VABORBACTAM FOR INJECTION - p. 790 261. MESNA - p. 793 262. METHADONE HYDROCHLORIDE - p. 796 263. METHOCARBAMOL - p. 796.e7 264. METHOTREXATE SODIUM - p. 797 265. METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA - p. 803 266. METHYLENE BLUE - p. 803.e5 267. METHYLERGONOVINE MALEATE - p. 803.e8 268. METHYLPREDNISOLONE SODIUM SUCCINATE - p. 805 269. METOCLOPRAMIDE HYDROCHLORIDE - p. 810 270. METOPROLOL TARTRATE - p. 813 271. METRONIDAZOLE HYDROCHLORIDE - p. 816 272. MICAFUNGIN SODIUM - p. 820 273. MILRINONE LACTATE - p. 824 274. MINOCYCLINE HYDROCHLORIDE - p. 827 275. MITOMYCIN - p. 827.e3 276. MITOXANTRONE HYDROCHLORIDE - p. 830 277. MOGAMULIZUMAB-kpkc - p. 833 278. MORPHINE SULFATE - p. 833.e3 279. MOSUNETUZUMAB - p. 838 280. MOXIFLOXACIN HYDROCHLORIDE - p. 844 281. MULTIVITAMIN INFUSION - p. 849 282. MYCOPHENOLATE MOFETIL HYDROCHLORIDE - p. 852 283. USUAL DOSE - p. 852 284. PEDIATRIC DOSE - p. 852 285. DOSE ADJUSTMENTS - p. 852 286. DILUTION - p. 852 287. COMPATIBILITY - p. 853 288. RATE OF ADMINISTRATION - p. 853 289. ACTIONS - p. 853 290. INDICATIONS AND USES - p. 853 291. CONTRAINDICATIONS - p. 853 292. PRECAUTIONS - p. 853 293. DRUG/LAB INTERACTIONS - p. 855 294. SIDE EFFECTS - p. 855 295. ANTIDOTE - p. 855 296. GENERIC DRUGS: N - p. e13 297. N - p. 856 298. GENERIC DRUGS: O - p. e14 299. O - p. 896.e1 300. GENERIC DRUGS: P - p. e15 301. P - p. 927 302. PACLITAXEL ■ PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) - p. 927 303. PALIFERMIN - p. 936 304. PALONOSETRON - p. 939 305. PAMIDRONATE DISODIUM - p. 941 306. PANITUMUMAB - p. 945 307. PANTOPRAZOLE SODIUM - p. 949 308. PAPAVERINE HYDROCHLORIDE - p. 952 309. PARICALCITOL - p. 954 310. PEGASPARGASE ■ ASPARAGINASE Erwinia chrysanthemi - p. 957 311. PEGLOTICASE - p. 957.e5 312. PEMBROLIZUMAB - p. 960 313. PEMETREXED - p. 968 314. PENICILLIN G AQUEOUS - p. 972 315. PENTAMIDINE ISETHIONATE - p. 976 316. PENTETATE CALCIUM TRISODIUM INJECTION ■ PENTETATE ZINC TRISODIUM INJECTION - p. 977 317. PENTOBARBITAL SODIUM - p. 977.e4 318. PENTOSTATIN - p. 979 319. PERAMIVIR - p. 982 320. PERTUZUMAB - p. 984 321. PHENOBARBITAL SODIUM - p. 989 322. PHENTOLAMINE MESYLATE - p. 991 323. PHENYLEPHRINE HYDROCHLORIDE - p. 991.e2 324. PHENYTOIN SODIUM - p. 993 325. PHOSPHATE - p. 998 326. PHYSOSTIGMINE SALICYLATE - p. 999 327. PHYTONADIONE - p. 1001 328. PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM - p. 1003 329. PLASMA PROTEIN FRACTION - p. 1007 330. POLATUZUMAB VEDOTIN-piiq - p. 1007.e2 331. POOLED PLASMA (HUMAN) - p. 1012 332. PORFIMER SODIUM - p. 1013 333. POSACONAZOLE - p. 1017 334. POTASSIUM ACETATE AND POTASSIUM CHLORIDE - p. 1021 335. PRALATREXATE - p. 1025 336. PRALIDOXIME CHLORIDE - p. 1029 337. PROCAINAMIDE HYDROCHLORIDE - p. 1029.e3 338. PROCHLORPERAZINE EDISYLATE - p. 1032 339. PROMETHAZINE HYDROCHLORIDE - p. 1035 340. PROPOFOL INJECTION - p. 1038 341. PROPRANOLOL HYDROCHLORIDE - p. 1043 342. PROTAMINE SULFATE - p. 1047 343. PROTEIN AMINO ACIDS, DEXTROSE, FAT EMULSION, AND ELECTROLYTES - p. 1049 344. PROTEIN (AMINO ACID) PRODUCTS - p. 1054 345. PROTEIN C CONCENTRATE (HUMAN) - p. 1054.e5 346. PROTHROMBIN COMPLEX CONCENTRATE (HUMAN) - p. 1054.e8 347. PYRIDOSTIGMINE BROMIDE - p. 1057 348. PYRIDOXINE HYDROCHLORIDE - p. 1057.e2 349. GENERIC DRUGS: R - p. e17 350. R - p. 1058 351. GENERIC DRUGS: S - p. e18 352. S - p. 1094 353. GENERIC DRUGS: T - p. e19 354. T - p. 1124 355. GENERIC DRUGS: V - p. e20 356. V - p. 1187 357. GENERIC DRUGS: Z - p. e21 358. Z - p. 1236 359. Appendix A. Recommendations for the Safe Use and Handling of Cytotoxic Drugs - p. 1248 360. Appendix B. FDA Pregnancy Categories - p. 1249 361. Appendix C. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - p. 1250 362. Appendix D. Information for Patients Receiving Immunosuppressive Agents - p. 1251 363. Appendix E. Recently Approved Drugs - p. 1252 364. Index - p. 1253 365. Solution Compatibility Chart - p. ES3
For nearly 50 years, Elsevier�s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2026 edition are many new monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
1. Elsevier’s 2026 Intravenous Medications : A Handbook for Nurses and Health Professionals - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. HOW TO USE - p. iii 6. HOW TO USE THIS BOOK - p. iii 7. Copyright - p. vi 8. Dedication - p. vii 9. PREFACE - p. ix 10. FORMAT AND CONTENT OF INTRAVENOUS MEDICATIONS - p. xiii 11. KEY TO ABBREVIATIONS - p. xvii 12. IMPORTANT IV THERAPY FACTS - p. xix 13. RESOURCES - p. xxi 14. PREPARATION AND ADMINISTRATION OF INJECTABLE DRUGS - p. xxiii 15. IV Drugs - p. xxvi 16. GENERIC DRUGS: A - p. e1 17. A - p. 1 18. ABATACEPT - p. 1 19. ACETAMINOPHEN - p. 4 20. ACETAZOLAMIDE SODIUM - p. 7 21. ACETYLCYSTEINE INJECTION - p. 8 22. ACYCLOVIR - p. 12 23. ADENOSINE - p. 15 24. ADUCANUMAB - p. 19 25. ALBUMIN (HUMAN) - p. 20 26. ALDESLEUKIN - p. 23 27. ALEMTUZUMAB - p. 29 28. ALLOPURINOL SODIUM - p. 37 29. ALPROSTADIL - p. 40 30. ALTEPLASE - p. 42 31. AMIKACIN SULFATE - p. 49 32. AMINOCAPROIC ACID - p. 52 33. AMINOPHYLLINE - p. 54 34. AMIODARONE HYDROCHLORIDE - p. 60 35. AMISULPRIDE - p. 66 36. AMPHOTERICIN B ■ AMPHOTERICIN B LIPID-BASED PRODUCTS - p. 68 37. AMPICILLIN SODIUM AND SULBACTAM SODIUM - p. 73 38. ANGIOTENSIN II INJECTION - p. 76 39. ANIDULAFUNGIN - p. 78 40. ANIFROLUMAB - p. 81 41. ANTIHEMOPHILIC FACTOR (HUMAN ■ RECOMBINANT ■ RECOMBINANT [Fc FUSION PROTEIN] ■ RECOMBINANT [PEGYLATED] ■ RECOMBINANT [PEGYLATED-aucl] ■ RECOMBINANT [SINGLE CHAIN] ■ RECOMBINANT [PORCINE SEQUENCE]) - p. 83 42. ANTIHEMOPHILIC FACTOR ■ VON WILLEBRAND FACTOR COMPLEX (HUMAN) - p. 94 43. ANTITHROMBIN III (HUMAN) - p. 100 44. ANTITHROMBIN RECOMBINANT - p. 103 45. USUAL DOSE (International units [IU]) - p. 103 46. DOSE ADJUSTMENTS - p. 103 47. DILUTION (International units [IU]) - p. 103 48. COMPATIBILITY - p. 104 49. RATE OF ADMINISTRATION (International units [IU]) - p. 104 50. ACTIONS (International units [IU]) - p. 104 51. INDICATIONS AND USES - p. 104 52. CONTRAINDICATIONS - p. 104 53. PRECAUTIONS - p. 104 54. DRUG/LAB INTERACTIONS - p. 105 55. SIDE EFFECTS - p. 105 56. ANTIDOTE - p. 105 57. ANTITHYMOCYTE GLOBULIN (RABBIT) - p. 105 58. ANTIVENIN (LATRODECTUS MACTANS) - p. 108 59. APREPITANT - p. 108.e2 60. ARGATROBAN - p. 110 61. ATEZOLIZUMAB - p. 114 62. ATROPINE SULFATE - p. 121 63. AVELUMAB - p. 123 64. Axatilimab - p. 128 65. AZACITIDINE - p. 130 66. AZITHROMYCIN - p. 134 67. AZTREONAM - p. 137 68. GENERIC DRUGS: B - p. e2 69. B - p. 140 70. GENERIC DRUGS: C - p. e3 71. C - p. 195 72. C1 ESTERASE INHIBITOR (HUMAN OR RECOMBINANT) - p. 195 73. CAFFEINE AND SODIUM BENZOATE - p. 198 74. CAFFEINE CITRATE - p. 198.e2 75. CALASPARGASE PEGOL-mknl - p. 200 76. CALCITRIOL - p. 203 77. CALCIUM CHLORIDE - p. 206 78. CALCIUM GLUCONATE - p. 208 79. CANGRELOR - p. 211 80. CARBOPLATIN - p. 213 81. CARFILZOMIB - p. 216 82. CARMUSTINE (BCNU) - p. 216.e10 83. CASIMERSEN - p. 219 84. CASPOFUNGIN ACETATE - p. 220 85. CEFAZOLIN SODIUM - p. 224 86. CEFEPIME AND ENMETAZOBACTAM - p. 227 87. CEFEPIME HYDROCHLORIDE - p. 229 88. CEFIDEROCOL - p. 233 89. CEFOTAXIME SODIUM - p. 236 90. CEFOTETAN DISODIUM - p. 239 91. CEFOXITIN SODIUM - p. 242 92. CEFTAROLINE FOSAMIL - p. 246 93. CEFTAZIDIME - p. 249 94. CEFTAZIDIME/AVIBACTAM - p. 253 95. CEFTOBIPROLE MEDOCARIL - p. 257 96. CEFTOLOZANE/TAZOBACTAM - p. 260 97. CEFTRIAXONE SODIUM - p. 262 98. CEFUROXIME SODIUM - p. 266 99. CEMIPLIMAB-rwlc - p. 269 100. CENTRUROIDES (SCORPION) IMMUNE F(ab’)2 (EQUINE) INJECTION - p. 273 101. CETIRIZINE HYDROCHLORIDE - p. 273.e2 102. CETUXIMAB - p. 274 103. CHLORAMPHENICOL SODIUM SUCCINATE - p. 279 104. USUAL DOSE - p. 279.e1 105. NEONATAL DOSE - p. 279.e1 106. DOSE ADJUSTMENTS - p. 279.e1 107. DILUTION - p. 279.e1 108. COMPATIBILITY - p. 279.e1 109. RATE OF ADMINISTRATION - p. 279.e1 110. ACTIONS - p. 279.e1 111. INDICATIONS AND USES - p. 279.e2 112. CONTRAINDICATIONS - p. 279.e2 113. PRECAUTIONS - p. 279.e2 114. DRUG/LAB INTERACTIONS - p. 279.e3 115. SIDE EFFECTS - p. 279.e3 116. ANTIDOTE - p. 279.e3 117. CHLOROTHIAZIDE SODIUM - p. 279.e3 118. CHLORPROMAZINE HYDROCHLORIDE - p. 281 119. CIPROFLOXACIN - p. 285 120. CISPLATIN - p. 291 121. CLADRIBINE - p. 294 122. CLEVIDIPINE BUTYRATE - p. 297 123. CLINDAMYCIN PHOSPHATE - p. 299 124. CLOFARABINE - p. 302 125. COAGULATION FACTOR VIIa (RECOMBINANT) RTS - p. 306 126. COAGULATION FACTOR X (HUMAN) - p. 309 127. COAGULATION FACTOR Xa (RECOMBINANT), INACTIVATED-zhzo - p. 312 128. COLISTIMETHATE SODIUM - p. 314 129. CONIVAPTAN HYDROCHLORIDE - p. 317 130. CONJUGATED ESTROGENS - p. 319 131. COPANLISIB - p. 319.e3 132. CORTICORELIN OVINE TRIFLUTATE - p. 319.e7 133. COSYNTROPIN - p. 319.e9 134. CRIZANLIZUMAB-tmca INJECTION - p. 320 135. CROTALIDAE IMMUNE F(ab’)2 (EQUINE) - p. 320.e2 136. CYCLOPHOSPHAMIDE - p. 320.e4 137. CYCLOSPORINE - p. 325 138. CYSTEINE HYDROCHLORIDE - p. 329 139. CYTARABINE - p. 333 140. CYTOMEGALOVIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) - p. 336 141. GENERIC DRUGS: D - p. e4 142. D - p. 338 143. DACARBAZINE - p. 338 144. DACTINOMYCIN - p. 339 145. DALBAVANCIN - p. 339.e3 146. DANTROLENE SODIUM - p. 341 147. DAPTOMYCIN - p. 344 148. DARATUMUMAB - p. 349 149. DARBEPOETIN ALFA - p. 349.e6 150. DAUNORUBICIN AND CYTARABINE LIPOSOME FOR INJECTION - p. 355 151. DAUNORUBICIN HYDROCHLORIDE ■ DAUNORUBICIN CITRATE LIPOSOMAL INJECTION - p. 359 152. DECITABINE FOR INJECTION - p. 362 153. DEFEROXAMINE MESYLATE - p. 365 154. DEFIBROTIDE - p. 365.e3 155. DELAFLOXACIN - p. 365.e6 156. DENILEUKIN DIFTITOX - p. 369 157. DESMOPRESSIN ACETATE - p. 369.e3 158. DEXAMETHASONE SODIUM PHOSPHATE - p. 372 159. DEXRAZOXANE - p. 377 160. DEXTRAN 1 - p. 380 161. DEXTRAN HIGH MOLECULAR WEIGHT - p. 380.e1 162. DEXTRAN LOW MOLECULAR WEIGHT - p. 382 163. DEXTROSE - p. 383 164. DIAZEPAM - p. 387 165. DIAZOXIDE - p. 390 166. DIFELIKEFALIN - p. 390.e2 167. DIGOXIN - p. 391 168. DIGOXIN IMMUNE FAB (OVINE) - p. 397 169. DIHYDROERGOTAMINE MESYLATE - p. 399 170. DILTIAZEM HYDROCHLORIDE - p. 401 171. DIMENHYDRINATE - p. 405 172. DINUTUXIMAB - p. 405.e2 173. DIPHENHYDRAMINE HYDROCHLORIDE - p. 410 174. DIPHTHERIA ANTITOXIN - p. 412 175. DIPYRIDAMOLE - p. 412.e2 176. USUAL DOSE - p. 413 177. DILUTION - p. 413 178. COMPATIBILITY - p. 413 179. RATE OF ADMINISTRATION - p. 413 180. ACTIONS - p. 413 181. INDICATIONS AND USES - p. 413 182. CONTRAINDICATIONS - p. 413 183. PRECAUTIONS - p. 413 184. DRUG/LAB INTERACTIONS - p. 414 185. SIDE EFFECTS - p. 414 186. ANTIDOTE - p. 414 187. DOBUTAMINE HYDROCHLORIDE - p. 414 188. DOCETAXEL - p. 417 189. Donanemab - p. 425 190. DOPAMINE HYDROCHLORIDE - p. 429 191. DOXAPRAM HYDROCHLORIDE - p. 433 192. DOXERCALCIFEROL - p. 433.e4 193. DOXORUBICIN HYDROCHLORIDE ■ DOXORUBICIN HYDROCHLORIDE LIPOSOMAL INJECTION - p. 437 194. DOXYCYCLINE HYCLATE - p. 443 195. DROPERIDOL - p. 446 196. DURVALUMAB - p. 446.e3 197. GENERIC DRUGS: E - p. e5 198. E - p. 451 199. GENERIC DRUGS: F - p. e6 200. F - p. 522 201. GENERIC DRUGS: G - p. e7 202. G - p. 595 203. GENERIC DRUGS: H - p. e8 204. H - p. 623 205. GENERIC DRUGS: I - p. e9 206. I - p. 648 207. IBALIZUMAB-uiyk - p. 648 208. IBANDRONATE SODIUM - p. 649 209. IBUPROFEN - p. 652 210. IBUPROFEN LYSINE - p. 656 211. IBUTILIDE FUMARATE - p. 658 212. IDARUBICIN HYDROCHLORIDE - p. 660 213. IDARUCIZUMAB - p. 663 214. IDURSULFASE - p. 665 215. IFOSFAMIDE - p. 665.e3 216. IMETELSTAT - p. 669 217. IMIGLUCERASE ■ VELAGLUCERASE ALFA - p. 671 218. IMIPENEM-CILASTATIN - p. 671.e4 219. IMIPENEM, CILASTATIN, AND RELEBACTAM - p. 675 220. IMMUNE GLOBULIN INTRAVENOUS - p. 679 221. INDOMETHACIN SODIUM - p. 688 222. INFLIXIMAB ■ INFLIXIMAB-dyyb ■ INFLIXIMAB-abda ■ INFLIXIMAB-axxq ■ INFLIXIMAB-qbtx - p. 691 223. INSULIN HUMAN ASPART or LISPRO or GLULISINE - p. 697 224. INOTUZUMAB OZOGAMICIN - p. 701 225. INSULIN HUMAN INJECTION (REGULAR) - p. 701.e5 226. INTERFERON ALFA-2b, RECOMBINANT - p. 705 227. IPILIMUMAB - p. 705.e4 228. IRINOTECAN HYDROCHLORIDE ■ IRINOTECAN LIPOSOME INJECTION - p. 706 229. IRON DEXTRAN INJECTION - p. 715 230. IRON SUCROSE - p. 717 231. ISATUXIMAB - p. 721 232. ISAVUCONAZONIUM SULFATE - p. 722 233. ISOPROTERENOL HYDROCHLORIDE - p. 725 234. USUAL DOSE - p. 726 235. PEDIATRIC DOSE - p. 727 236. DOSE ADJUSTMENTS - p. 727 237. DILUTION - p. 727 238. COMPATIBILITY - p. 727 239. RATE OF ADMINISTRATION - p. 727 240. ACTIONS - p. 727 241. INDICATIONS AND USES - p. 728 242. CONTRAINDICATIONS - p. 728 243. PRECAUTIONS - p. 728 244. DRUG/LAB INTERACTIONS - p. 729 245. SIDE EFFECTS - p. 729 246. ANTIDOTE - p. 729 247. IXABEPILONE - p. 729 248. GENERIC DRUGS: K - p. e10 249. K - p. 734 250. GENERIC DRUGS: L - p. e11 251. L - p. 736 252. GENERIC DRUGS: M - p. e12 253. M - p. 776 254. MAGNESIUM SULFATE - p. 776 255. MANNITOL - p. 779 256. MECHLORETHAMINE HYDROCHLORIDE - p. 783 257. MELOXICAM INJECTION - p. 783.e2 258. MEPERIDINE HYDROCHLORIDE - p. 786 259. MEROPENEM - p. 786.e5 260. MEROPENEM AND VABORBACTAM FOR INJECTION - p. 790 261. MESNA - p. 793 262. METHADONE HYDROCHLORIDE - p. 796 263. METHOCARBAMOL - p. 796.e7 264. METHOTREXATE SODIUM - p. 797 265. METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA - p. 803 266. METHYLENE BLUE - p. 803.e5 267. METHYLERGONOVINE MALEATE - p. 803.e8 268. METHYLPREDNISOLONE SODIUM SUCCINATE - p. 805 269. METOCLOPRAMIDE HYDROCHLORIDE - p. 810 270. METOPROLOL TARTRATE - p. 813 271. METRONIDAZOLE HYDROCHLORIDE - p. 816 272. MICAFUNGIN SODIUM - p. 820 273. MILRINONE LACTATE - p. 824 274. MINOCYCLINE HYDROCHLORIDE - p. 827 275. MITOMYCIN - p. 827.e3 276. MITOXANTRONE HYDROCHLORIDE - p. 830 277. MOGAMULIZUMAB-kpkc - p. 833 278. MORPHINE SULFATE - p. 833.e3 279. MOSUNETUZUMAB - p. 838 280. MOXIFLOXACIN HYDROCHLORIDE - p. 844 281. MULTIVITAMIN INFUSION - p. 849 282. MYCOPHENOLATE MOFETIL HYDROCHLORIDE - p. 852 283. USUAL DOSE - p. 852 284. PEDIATRIC DOSE - p. 852 285. DOSE ADJUSTMENTS - p. 852 286. DILUTION - p. 852 287. COMPATIBILITY - p. 853 288. RATE OF ADMINISTRATION - p. 853 289. ACTIONS - p. 853 290. INDICATIONS AND USES - p. 853 291. CONTRAINDICATIONS - p. 853 292. PRECAUTIONS - p. 853 293. DRUG/LAB INTERACTIONS - p. 855 294. SIDE EFFECTS - p. 855 295. ANTIDOTE - p. 855 296. GENERIC DRUGS: N - p. e13 297. N - p. 856 298. GENERIC DRUGS: O - p. e14 299. O - p. 896.e1 300. GENERIC DRUGS: P - p. e15 301. P - p. 927 302. PACLITAXEL ■ PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) - p. 927 303. PALIFERMIN - p. 936 304. PALONOSETRON - p. 939 305. PAMIDRONATE DISODIUM - p. 941 306. PANITUMUMAB - p. 945 307. PANTOPRAZOLE SODIUM - p. 949 308. PAPAVERINE HYDROCHLORIDE - p. 952 309. PARICALCITOL - p. 954 310. PEGASPARGASE ■ ASPARAGINASE Erwinia chrysanthemi - p. 957 311. PEGLOTICASE - p. 957.e5 312. PEMBROLIZUMAB - p. 960 313. PEMETREXED - p. 968 314. PENICILLIN G AQUEOUS - p. 972 315. PENTAMIDINE ISETHIONATE - p. 976 316. PENTETATE CALCIUM TRISODIUM INJECTION ■ PENTETATE ZINC TRISODIUM INJECTION - p. 977 317. PENTOBARBITAL SODIUM - p. 977.e4 318. PENTOSTATIN - p. 979 319. PERAMIVIR - p. 982 320. PERTUZUMAB - p. 984 321. PHENOBARBITAL SODIUM - p. 989 322. PHENTOLAMINE MESYLATE - p. 991 323. PHENYLEPHRINE HYDROCHLORIDE - p. 991.e2 324. PHENYTOIN SODIUM - p. 993 325. PHOSPHATE - p. 998 326. PHYSOSTIGMINE SALICYLATE - p. 999 327. PHYTONADIONE - p. 1001 328. PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM - p. 1003 329. PLASMA PROTEIN FRACTION - p. 1007 330. POLATUZUMAB VEDOTIN-piiq - p. 1007.e2 331. POOLED PLASMA (HUMAN) - p. 1012 332. PORFIMER SODIUM - p. 1013 333. POSACONAZOLE - p. 1017 334. POTASSIUM ACETATE AND POTASSIUM CHLORIDE - p. 1021 335. PRALATREXATE - p. 1025 336. PRALIDOXIME CHLORIDE - p. 1029 337. PROCAINAMIDE HYDROCHLORIDE - p. 1029.e3 338. PROCHLORPERAZINE EDISYLATE - p. 1032 339. PROMETHAZINE HYDROCHLORIDE - p. 1035 340. PROPOFOL INJECTION - p. 1038 341. PROPRANOLOL HYDROCHLORIDE - p. 1043 342. PROTAMINE SULFATE - p. 1047 343. PROTEIN AMINO ACIDS, DEXTROSE, FAT EMULSION, AND ELECTROLYTES - p. 1049 344. PROTEIN (AMINO ACID) PRODUCTS - p. 1054 345. PROTEIN C CONCENTRATE (HUMAN) - p. 1054.e5 346. PROTHROMBIN COMPLEX CONCENTRATE (HUMAN) - p. 1054.e8 347. PYRIDOSTIGMINE BROMIDE - p. 1057 348. PYRIDOXINE HYDROCHLORIDE - p. 1057.e2 349. GENERIC DRUGS: R - p. e17 350. R - p. 1058 351. GENERIC DRUGS: S - p. e18 352. S - p. 1094 353. GENERIC DRUGS: T - p. e19 354. T - p. 1124 355. GENERIC DRUGS: V - p. e20 356. V - p. 1187 357. GENERIC DRUGS: Z - p. e21 358. Z - p. 1236 359. Appendix A. Recommendations for the Safe Use and Handling of Cytotoxic Drugs - p. 1248 360. Appendix B. FDA Pregnancy Categories - p. 1249 361. Appendix C. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - p. 1250 362. Appendix D. Information for Patients Receiving Immunosuppressive Agents - p. 1251 363. Appendix E. Recently Approved Drugs - p. 1252 364. Index - p. 1253 365. Solution Compatibility Chart - p. ES3
